Last Transcript: Metsera, Inc.

Date Insider Type Main position Quantity % Market Cap. Importance
11/13/25 Issuer sale

Chief Technology Officer

579,581 0.5504%
11/13/25
Fidelity Management & Research Co. LLC
OthersCompany 2,230,450 2.1183%
11/13/25 Issuer sale

Chief Financial Officer

788,314 0.7487%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-15.24% - - 7.43B
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.54%-1.27%+35.46%+74.97% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+3.63%+4.22%+25.33%-14.56% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
Average -0.83%-2.20%+30.07%+232.40% 30.1B
Weighted average by Cap. -0.90%-1.32%+31.79%+158.17%
Logo Metsera, Inc.
Metsera Inc is a United States-based biopharmaceutical company. The Company is engaged in developing medicines and solutions for obesity and metabolic diseases. It offers a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with profiles to address multiple therapeutic targets and meet the future needs of a weight loss treatment landscape. Its solutions helps to reduce the physical, emotional, and economic burdens of obesity as a driver of diseases. In addition it offers HALO, which is a peptide lipidation platform technology, which enables peptides to bind simultaneously to albumin and to a drug target.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. MTSR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!